ICAM2 and neuroblastoma: We altered the glycosylation status of ICAM-2 by substitution of alanines for asparagines, to prevent glycosylation at specific residues that comprise N-linked glycosylation sites in situ; and then determined whether substitutions modulated the ability of ICAM-2 to suppress metastatic properties of NB cells.